InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

ABA Committee Urges Inclusion of Alternative Licensure Pathways Language in Accreditation Standards The Standards Committee reviewed Standard 316 in light of the recent developments that several U.S.

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Welcome to Edition 8.32 of the Rocket Report! The big news this week is NASA’s shake-up of the Artemis program. On paper, at ...

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

To learn more about our editorial approach, explore The Direct Message methodology. Denise, a 38-year-old paralegal in Tampa, doesn’t smoke. She’s never touched a cigarette. She runs three mornings a ...

Gelatine Sculpt is a liquid dietary supplement positioned as a premium, holistic evolution of the gelatin trick. Marketed as a "Bariatric Jelly" alternative, Gelatine Sculpt is designed to be taken as ...